Skip to main content

Molecular Devices Posts Flat Q4 Revenue and R&D Spend as Profit Tumbles 31 Percent

NEW YORK (GenomeWeb News) — Molecular Devices today said fourth-quarter revenues remained virtually flat as R&D spending was unchanged and profit decreased 31 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $52.8 million from $52.7 million year over year.
 
Molecular Devices did not break out revenues by business unit.
 
R&D spending was flat at $6.3 million in both quarters.
 
The company said profit declined to $4 million from $5.8 million in the year-ago period.
 
Molecular Devices said it had around $22.8 million in cash and equivalents as of Dec. 31.
 
Last week MDS said it plans to acquire Molecular Devices for $615 million in cash.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.